SCHEMBL2576883

SCHEMBL2576883

Cc1nc(C2=CCC(Cl)(c3ccc4c(c3)CN(C(=O)OC(C)(C)C)Cc3nncn3-4)CC2)cs1

nearest known ligand 0.32

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
MAP3K5 Q99683 3/20 0.32
ESR2 Q92731 1/20 0.30
CASP3 P42574 1/20 0.30
CASP2 P42575 1/20 0.30
OXTR P30559 1/20 0.30
AVPR1A P37288 1/20 0.30
GRM5 P41594 1/20 0.30
GRM1 Q13255 1/20 0.30
DDB1 Q16531 1/20 0.30
CRBN Q96SW2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2563857 0.86 GRM5 (0.36) MAP3K5ESR2OXTRAVPR1AGRM5
SCHEMBL2580101 0.85 HDAC2 (0.34) MAP3K5ESR2OXTRAVPR1AGRM5
SCHEMBL2577696 0.84 CDK9 (0.34) MAP3K5ESR2OXTRAVPR1AGRM5
SCHEMBL2574373 0.83 CYP11B2 (0.34) MAP3K5ESR2OXTRAVPR1ADDB1
SCHEMBL2574177 0.81 GRM5 (0.38) MAP3K5ESR2OXTRAVPR1AGRM5
SCHEMBL2578851 0.81 MAP3K5 (0.33) MAP3K5ESR2OXTRAVPR1AGRM5
SCHEMBL2573980 0.81 DDB1 (0.38) MAP3K5ESR2OXTRAVPR1ADDB1
SCHEMBL2575034 0.81 GPR119 (0.33) OXTR
SCHEMBL2574375 0.81 CDK9 (0.35) MAPTMAP3K5GRM5GRM1
SCHEMBL2573984 0.80 HSD11B1 (0.35) MAP3K5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2558467-A1 ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E]AZULENES AS VASOPRESSIN ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2013-02-20 EP disclosed
WO-2011128265-A1 ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E] AZULENES AS VASOPRESSIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-10-20 WO disclosed